New number of shares and votes in Wilson Therapeutics

Following the recent directed share issue, the number of shares and votes in Wilson Therapeutics AB (publ) has increased by 2,572,024.

Today, the last trading day of the month, there are in total 28,292,272 shares and votes in Wilson Therapeutics.

For further information contact:
Anders Martin-Löf, CFO, Wilson Therapeutics AB
Telephone: +46 8 796 00 00
Email: anders.martin-lof@wtx.se
   
Wilson Therapeutics AB (publ)
Corp. Reg. No.556893-0357
Kungsgatan 3
SE-111 43 Stockholm
 
About Wilson Therapeutics

Wilson Therapeutics is a biopharmaceutical company, based in Stockholm, Sweden, that develops novel therapies for patients with rare copper-mediated disorders. Wilson Therapeutics’ lead product, WTX101, is in development as a novel treatment for Wilson Disease. A Phase 2 clinical study has been successfully completed and preparations for a pivotal Phase 3 study are ongoing. Wilson Therapeutics is listed in the Mid Cap segment on Nasdaq Stockholm with the stock ticker WTX.

 
Visit www.wilsontherapeutics.com for more information.
 
   
The information in the press release is information that Wilson Therapeutics is obliged to make public pursuant to the Swedish Financial Instruments Trading Act. The information was submitted for publication, through the agency of the contact person set out above, at 07.00 CET on December 29, 2017.
 

Tags:

About Us

Wilson Therapeutics is a biopharmaceutical company, based in Stockholm, Sweden, that develops novel therapies for patients with rare diseases. Wilson Therapeutics’ lead product, Decuprate, is initially being developed as a novel treatment for Wilson Disease. Wilson Therapeutics is listed in the Mid Cap segment on Nasdaq Stockholm with the stock ticker WTX.

Subscribe

Documents & Links